A retrospective cohort study of 5,796 cancer patients treated with immune checkpoint inhibitors finds that statin therapy is guideline-indicated for many patients, yet nearly half remain untreated. Among 2,058 patients with formal indications at checkpoint start, 46% did not receive statins. The analysis also reports no measurable increase in immune-related adverse events such as myositis or hepatitis among statin users, with hazard estimates showing no significant differences. However, statin use likewise showed no clear reduction in acute coronary syndrome or overall mortality. Clinically, the immediate action point is implementation: even if outcome benefits remain uncertain, underutilization of guideline cardiovascular protection in an immunotherapy population is quantifiably widespread.